Synaptogenix Inc (SNPX)

[SF Wolf]

Drilling down into the data paid off big time:

"The post-hoc analysis comparing SIB scores in non-memantine versus memantine patients found the following:

At week 15, non-memantine patients in the mITT Group treated with 20µg (n=14) showed an SIB improvement of 5.88, while the placebo patients (n=11) showed a decline in their SIB scores of -0.05 for an overall treatment ? of 5.93 from baseline (p=0.0576).

At week 15, non-memantine patients in the Completers Group treated with 20µg (n=14) showed an SIB improvement of 6.24, while the placebo patients (n=11) showed a decline in their SIB scores of -0.12 for an overall treatment ? of 6.36 from baseline (p=0.0488).

Patients taking memantine as background therapy in the 20µg (n=20) and control (n=22) groups showed no improvement in SIB scores."